• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.

作者信息

Tahri Sabrin, Piccinelli Sara, Su Nang Kham, Lampe Luisa, Dong Han, Vergara Cadavid Juliana, Boiarsky Rebecca, Papazian Natalie, Lightbody Elizabeth D, Cao Amanda, Alberge Jean-Baptiste, Ferrari de Andrade Lucas, Rahmat Mahshid, Shen Yujia, Blanco Fernández Laura, Zabaleta Aintzane, Günther Andreas, Getz Gad, Sonneveld Pieter, Cupedo Tom, Wucherpfennig Kai W, Ghobrial Irene M, Romee Rizwan

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Department of Medical Oncology, Harvard Medical School, Boston, MA.

出版信息

Blood Adv. 2024 Oct 22;8(20):5365-5370. doi: 10.1182/bloodadvances.2023010869.

DOI:10.1182/bloodadvances.2023010869
PMID:39106432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11568787/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11568787/c202042eb49a/BLOODA_ADV-2023-010869-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11568787/3b3745e550dd/BLOODA_ADV-2023-010869-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11568787/c202042eb49a/BLOODA_ADV-2023-010869-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11568787/3b3745e550dd/BLOODA_ADV-2023-010869-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3ef/11568787/c202042eb49a/BLOODA_ADV-2023-010869-gr2.jpg

相似文献

1
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.抑制MICA和MICB脱落可增强记忆样自然杀伤细胞对多发性骨髓瘤的细胞毒性作用。
Blood Adv. 2024 Oct 22;8(20):5365-5370. doi: 10.1182/bloodadvances.2023010869.
2
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.抑制糖原合酶激酶-3可增加多发性骨髓瘤细胞中 NKG2D 配体 MICA 的表达，并增加其对 NK 细胞介导的细胞毒性的敏感性：STAT3 的作用。
J Immunol. 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17.
3
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.HLA I类分子、NKG2D和自然细胞毒性受体调节自然杀伤细胞对多发性骨髓瘤细胞的识别。
Blood. 2005 Jan 1;105(1):251-8. doi: 10.1182/blood-2004-04-1422. Epub 2004 Aug 24.
4
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.抑制溴结构域和额外末端（BET）蛋白可增加NKG2D配体MICA的表达，并增强多发性骨髓瘤细胞对自然杀伤（NK）细胞介导的细胞毒性的敏感性：cMYC-IRF4-miR-125b相互作用的作用
J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2.
5
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.肝 X 受体的激活通过不同的分子机制上调多发性骨髓瘤中 NKG2D 配体 MICA 和 MICB 的表达。
FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24.
6
Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.肼屈嗪和丙戊酸上调 NKG2D 配体并增强自然杀伤细胞的细胞毒性。
Int J Oncol. 2011 Dec;39(6):1491-9. doi: 10.3892/ijo.2011.1144. Epub 2011 Jul 26.
7
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.NEDD8-激活酶抑制在多发性骨髓瘤中的免疫调节作用：NKG2D 配体的上调和对自然杀伤细胞识别的敏感性。
Cell Death Dis. 2021 Sep 4;12(9):836. doi: 10.1038/s41419-021-04104-w.
8
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.热休克蛋白90抑制剂可增加多发性骨髓瘤细胞上MHC I类相关链A和B配体的表达及其触发自然杀伤细胞脱颗粒的能力。
J Immunol. 2009 Oct 1;183(7):4385-94. doi: 10.4049/jimmunol.0901797. Epub 2009 Sep 11.
9
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.卡非佐米增强自然杀伤细胞介导的骨髓瘤细胞裂解，这与人类白细胞抗原I类分子表达降低有关。
Oncotarget. 2015 Sep 29;6(29):26982-94. doi: 10.18632/oncotarget.4831.
10
[Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].[多药耐药鼻咽癌细胞系CNE2/DDP中NKG2D配体的表达及其对自然杀伤细胞细胞毒性的影响]
Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jun;27(6):887-9.

引用本文的文献

1
tRNA-derived small RNA 3' tRF-Ala CGC obstructs NK cytotoxicity via cleavage of membrane protein MICA in colorectal cancer.tRNA衍生的小RNA 3'tRF-Ala CGC通过切割结直肠癌中的膜蛋白MICA来阻碍自然杀伤细胞的细胞毒性。
Front Immunol. 2025 Jul 14;16:1620550. doi: 10.3389/fimmu.2025.1620550. eCollection 2025.

本文引用的文献

1
A vaccine targeting resistant tumours by dual T cell plus NK cell attack.一种通过双重 T 细胞加自然杀伤细胞攻击来靶向耐药肿瘤的疫苗。
Nature. 2022 Jun;606(7916):992-998. doi: 10.1038/s41586-022-04772-4. Epub 2022 May 25.
2
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.输注供体记忆样自然杀伤细胞治疗移植后复发的扩增、持续和疗效。
J Clin Invest. 2022 Jun 1;132(11). doi: 10.1172/JCI154334.
3
Harnessing natural killer cells for the treatment of multiple myeloma.利用自然杀伤细胞治疗多发性骨髓瘤。
Semin Oncol. 2022 Feb;49(1):69-85. doi: 10.1053/j.seminoncol.2022.01.004. Epub 2022 Jan 21.
4
Natural Killer Cells in the Malignant Niche of Multiple Myeloma.自然杀伤细胞在多发性骨髓瘤的恶性微环境中。
Front Immunol. 2022 Jan 11;12:816499. doi: 10.3389/fimmu.2021.816499. eCollection 2021.
5
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.供体记忆样 NK 细胞在移植后复发的儿童 AML 患者中持续存在并诱导缓解。
Blood. 2022 Mar 17;139(11):1670-1683. doi: 10.1182/blood.2021013972.
6
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.多发性骨髓瘤的微环境由炎症性基质细胞景观定义。
Nat Immunol. 2021 Jun;22(6):769-780. doi: 10.1038/s41590-021-00931-3. Epub 2021 May 20.
7
NK cells for cancer immunotherapy.自然杀伤细胞用于癌症免疫疗法。
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. doi: 10.1038/s41573-019-0052-1. Epub 2020 Jan 6.
8
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.MICA-129 二态性和可溶性 MICA 与多发性骨髓瘤的进展相关。
Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. eCollection 2018.
9
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.抗体依赖的细胞吞噬作用是依鲁替尼作用的新机制。
Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.
10
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.抗体介导的 MICA 和 MICB 脱落抑制促进 NK 细胞驱动的肿瘤免疫。
Science. 2018 Mar 30;359(6383):1537-1542. doi: 10.1126/science.aao0505.